Top-Level industry professionals speak at Pain Therapeutics Conference in 2 weeks

LONDON - April 30, 2020 - PRLog -- The highly anticipated 20th Annual Pain Therapeutics Conference will reconvene on 11th and 12th May 2020 via virtual conference, online access only due to the recent COVID-19 outbreak and concerns of public gatherings.

The two-day event will feature a variety of key top-level industry professionals from the pain and analgesic pharmaceutical industry to meet and discuss all areas of pain therapeutics, such as pain treatment highlighting clinical success to date as well as evaluating the potential of drug candidates in the pipelines of the top pharmaceutical organisations.

For those interested in attending, registration is available at http://www.pain-therapeutics.co.uk/PR5

Pain Therapeutics will highlight key themes led by top pharmaceutical companies include:

Theme: Pain Research Essentials
Richard Malamut, Chief Medical Officer and SVP R&D, Collegium Pharma on 'Rethink pain research by exploring novel biomarkers, sex differences in nociception, pain clinical trial design and novel targets' covering:
• Evaluating the role of biomarkers in pain research
• Identifying biomarkers – where are we now?
• Establishing biomarkers in patient populations
• Highlighting the importance of biomarker discovery and its contribution to early stage studies on pain

Theme: Analgesic Drug Development
Zahid Ali, Head Clinical Pharmacology and Translational Medicine, Mundipharma Research Limited on B'ridging the translational gap in analgesic drug development' covering:
• What have we learnt from over 20 years of concerted analgesic drug development?
• The integration of clinical, non-clinical and disease area knowledge for more effective decision making
• The impact of new technologies on translational approaches in analgesic drug development
• One size does not fit all- developing more targeted and effective analgesics

Theme: Novel Discoveries in Pain Therapy
Paul Ratcliffe, Vice President, Setup Innovation Hubs R&D, Grunenthal Group on 'Emphasising Disease Understanding to deliver effective pain treatments. Exploring NOP receptor pharmacology as an exciting opportunity to treat neuronal hypersensitivity driven pain disorders' covering:
• Grunenthal's approach to tackle the underlying pathophysiologies of pain
• Targeting the nociception/orphanin FQ peptide (NOP) receptor; a journey navigating between the pre-clinic and clinical environment

Theme: The Opioid Crisis and Non-Opioid Alternatives
James Campbell, Chief Scientific Officer, Centrexion Therapeutics Corp on 'Evaluation of the Selective Cannabinoid 2 Receptor Agonist CNTX-6016 for the Treatment of Neurophatic pain'.

This conference is CPD Accredited.

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk

Pain Therapeutics 2020
Conference: 11th – 12th May 2020
Virtual Conference  - Online Access Only
www.pain-therapeutics.co.uk/PR5
#SMiPain